Related Experiment Video
Updated: Jun 27, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Effects of macrolides on proinflammatory epitopes on endothelial cells in vitro
Michael Millrose1, Matthias Kruse, Burkhard Flick
1Institute of Clinical Pharmacology and Toxicology, Charité, Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Abstract:
An inflammatory reaction at the site of infusion is a common clinical problem that is observed after the intravenous application of antibiotics and other drugs. The pathomechanism of this infusion-related phlebitis is not fully understood. We analyzed the effects of the three macrolide antibiotics erythromycin, clarithromycin and azithromycin on human endothelial cells in vitro. As a positive control quinupristin/dalfopristin was studied. The cytotoxicity of all substances was analyzed by a modified MTT cytotoxicity assay with 3T3-fibroblasts and EA.hy 926 endothelial cells. Cells were incubated for 10 days with the antibiotics. After adding MTT the optical density was measured which correlates with cell death. Clarithromycin exhibited the strongest cytotoxic effect on EA.hy 926 cells (EC(50) 30 mg/L), followed by azithromycin (EC(50) 40 mg/L), a cytotoxic effect of erythromycin could only be observed at much higher concentrations (EC(50) 310 mg/L). The reaction of the endothelial cells was further analyzed in detail by means of flow cytometry. For these experiments the endothelial cell line EA.hy 926 as well as primary cells (HUVEC) were used. The antigens were stained with fluoresceinisothiocyanat- or phycoerythrin-conjugated monoclonal antibodies for the following surface antigens: CD34, E-selectin (CD62E), ICAM-1 (CD54) and VCAM-1 (CD106). Cells were incubated with the antibiotics at concentrations ranging from 100 to 800 mg/L (clarithromycin and azithromycin) and from 200 to 1,200 mg/L (erythromycin). These concentrations occur under therapeutic conditions at the site of infusion. Cells were incubated for 2 h and analysis was carried out after an additional culture period of 22 h without test compounds. A significantly enhanced expression of all four antigens was observed which was most pronounced at 800 mg/L (erythromycin), 600 mg/L (azithromycin) and 400 mg/L (clarithromycin). A concentration of 800 mg/L erythromycin medium caused an increase of the expression of CD34 (+6%), E-selectin (+5%), ICAM-1 (+14%) and VCAM-1 (+5%). At lower concentrations (600 mg/L) azithromycin provokes a stronger upregulation of the proinflammatory antigens: CD34 (+17%), E-selectin (+18%), ICAM-1 (+27%) and VCAM-1 (+17%). At a concentration of 400 mg/L medium clarithromycin induced a similar effect as erythromycin at twice this concentration: CD34 (+5%), E-selectin (+7%), ICAM-1 (+23%) and VCAM-1 (+4%). Reactions of the HUVECs were less pronounced than those of the EA.hy 926 cells. Cell surface markers involved in interactions between endothelial cells and leukocytes proved to be useful markers to study differences in the proinflammatory potential of the three macrolides. By analysing the upregulation of these antigens on EA.hy 926 cells in vitro the risk of phlebitis could be predictable for other drugs as well.
Insights
Clarithromycin, azithromycin, and erythromycin can cause inflammation at infusion sites. This study found clarithromycin and azithromycin more significantly increase inflammatory markers on endothelial cells, suggesting a higher phlebitis risk.
Area of Science:
- Pharmacology
- Cell Biology
- Immunology
Background:
- Infusion-related phlebitis is a common complication of intravenous drug administration.
- The exact mechanisms underlying infusion-related phlebitis are not fully understood.
- Macrolide antibiotics are frequently used intravenously, necessitating an understanding of their local effects.
Purpose of the Study:
- To investigate the in vitro effects of erythromycin, clarithromycin, and azithromycin on human endothelial cells.
- To assess the potential of these macrolides to induce inflammatory responses relevant to phlebitis.
- To evaluate the cytotoxicity and pro-inflammatory potential of macrolides on endothelial cells.
Main Methods:
- Cytotoxicity was assessed using a modified MTT assay on 3T3-fibroblasts and EA.hy 926 endothelial cells.
- Endothelial cells (EA.hy 926 and primary HUVECs) were incubated with macrolides at therapeutic concentrations.
- Flow cytometry analyzed the expression of surface antigens (CD34, E-selectin, ICAM-1, VCAM-1) after drug exposure.
Main Results:
- Clarithromycin and azithromycin demonstrated significant cytotoxicity to EA.hy 926 cells at lower concentrations than erythromycin.
- All three macrolides upregulated inflammatory markers (CD34, E-selectin, ICAM-1, VCAM-1) on endothelial cells.
- Azithromycin and clarithromycin induced a more pronounced upregulation of these inflammatory markers compared to erythromycin at similar concentrations.
Conclusions:
- Macrolide antibiotics, particularly clarithromycin and azithromycin, can induce pro-inflammatory responses in endothelial cells in vitro.
- Upregulation of cell adhesion molecules correlates with the inflammatory potential of macrolides.
- Assessing endothelial cell surface marker expression may predict the risk of phlebitis for various drugs.

